After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Investor's Business Daily on MSN2h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
7don MSN
We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...
We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...
One of Europe's most significant strategic assets is the life science industry, which produces cutting-edge drugs and vaccines essential to the ... European Life Science Tools and Reagents Market ...
At its peak, the drug could generate over $6 billion in revenue for Merck. The company also expects ... Rounding out this list of high-yielding stocks is Swiss pharmaceutical giant Novartis ...
Merck & Co has axed two hepatitis drugs in its pipeline ... a deep undercutting of Epclusa’s list price of $74,760 for a 12 week course - and analysts think this move could spark a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback